Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMPKT: Metformin and Empagliflozin for Metabolic Profiling After Kidney Transplantation
NCT05013112Completed
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jan 2023
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial in metabolic disorder comparing Placebo group, Metformin group and Empagliflozin (3 arms). Primary endpoint: Differences in the visceral-to-subcutaneous fat area ratio at 12 months. Started Jan 2023; status: completed.
02
Drugs
metforminempagliflozin
03
Conditions
metabolic disorder
Beyond the preview
Go deeper on NCT05013112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05013112.